Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : YEEHAW CANDIDATES -- Ignore unavailable to you. Want to Upgrade?

To: ACAN who wrote (19900)	10/27/2006 2:12:04 PM
From: Galirayo	Respond to of 23958

[HSR] Allan .. it's getting into DeCat catagory ... But it looks like it's going to be run over by the next Semi that goes by. That's a Halloween Chart allright !!! Spooooooky !! Where are the Gapology Experts when there's one begging to be filled ?? stockcharts.com

To: ACAN who wrote (19900)	11/2/2006 7:17:30 AM
From: J.F.	Read Replies (3) \| Respond to of 23958

XOMA has some early news out - Japan's Takeda Pharmaceutical Co. (4502.TO) and XOMA Ltd. (XOMA) of the U.S. said Thursday they have agreed to tie up in the research and development of therapeutic antibodies. The two companies said in a joint statement that Takeda's payments to XOMA could exceed $100 million, excluding royalties, throughout their alliance. Takeda will make upfront and milestone payments to XOMA and fund its research and development activities including the manufacturing of antibodies for preclinical and clinical trials. The Japanese company will also pay royalties on sales of successfully developed products. XOMA will discover therapeutic antibodies against multiple targets selected by Takeda, they said. jf...